Health ProductsDear Healthcare Professional Letter

Association of Avandia (rosiglitazone) and Avandamet (rosiglitazone/metformin) with new onset and/or worsening of macular edema - For Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from GlaxoSmithKline Inc. Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Health Canada Endorsed Important Safety Information on Avandia® (rosiglitazone maleate) and Avandamet® (rosiglitazone maleate/metformin hydrochloride)

December 19, 2005

Subject: Association of PrAvandia® and PrAvandamet® with new onset and/or worsening of macular edema

Dear Health Care Professional,

GlaxoSmithKline Inc. (GSK) in consultation with Health Canada would like to inform you of new safety information regarding rosiglitazone-containing products Avandia® (rosiglitazone maleate) tablets and Avandamet® (rosiglitazone maleate/metformin hydrochloride) tablets. These products are anti-diabetic therapies used in treating type 2 diabetes mellitus. Rare post-market reports of serious adverse events, describing visual impairment due to new onset and/or worsening of macular edema have been received, including reports originating in Canada. In some cases, the visual impairment was reported to have improved or resolved following discontinuation of Avandia or Avandamet. In the majority of cases, patients also reported fluid retention, peripheral edema or weight gain. Reports received include patients using rosiglitazone both as monotherapy and in combination with other hypoglycemic agents.

  • New onset and/or worsening of macular edema has been reported in diabetic patients treated with the rosiglitazone containing products, Avandia® and Avandamet®.
  • Discontinuation of Avandia®/Avandamet® should be considered in patients reporting visual deterioration and ophthalmological consultation should be sought.
  • Avandia®/Avandamet® should be used with caution in patients with pre-existing diagnosis of macular edema or diabetic retinopathy.

Macular edema typically occurs in association with diabetic retinopathy, although it is more likely to occur as retinopathy progresses. Risk factors for macular edema include duration of diabetes, presence of retinopathy, hypertension, and poor glycemic control. Symptoms suggestive of macular edema include blurred or distorted vision, decreased colour sensitivity, and decreased dark adaptation.

GSK is sending this letter in order to highlight this important new safety information and the Canadian product monographs for Avandia® and Avandamet® will be updated. Health Canada will review this new information for Avandia® and Avandamet® and will do so for similar anti-diabetic drugs.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious macular edema or other serious or unexpected adverse reactions in patients receiving Avandia® or Avandamet® should be reported to GlaxoSmithKline or Health Canada at the following addresses:

GlaxoSmithKline Inc
7333 Mississauga Rd.
Mississauga, Ontario
L5N 6L4
Tel: 1-800-387-7374

Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Health Canada
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca

The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
mhpd_dpsc@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738

Your professional commitment in this regard has an important role in protecting the well-being of your patients by contributing to early signal detection and informed drug use.

Any questions from health care professionals may be directed to our Medical Information department via GSK Customer Service at 1-800-387-7374.

Sincerely

original signed by

Dr. John A Dillon MBBCh MFPM
VP, Medical Division and Chief Medical Officer

GlaxoSmithKline Inc.

Avandia® and Avandamet® are registered trademarks, used under license by GlaxoSmithKline

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime